Ensitrelvir Shows Promise as Effective COVID-19 Antiviral in Phase 2 Trial
A new study published in the journal of The Lancet Infectious Diseases showed that an efficient substitute for current COVID-19 therapies is ensitrelvir, a once-daily oral SARS-CoV-2 protease inhibitor developed by Shionogi. The current oral first-line …